Fields of Application:
Diabetes II
Active Substance:
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) analog. As GLP-1, liraglutide induces insulin secretion from β-cells by binding to GLP receptors in the pancreas.
Liraglutide is
*The following content is generated by AI and is for reference only.
Overview
Liraglutide is a GLP-1 receptor agonist synthesized via solid-phase peptide synthesis. It mimics human glucagon-like peptide-1 to regulate glucose metabolism. Molecular Formula: C204H316N54O60S; CAS No.: 204656-20-2.
Application
- Pharmaceutical Manufacturing: Production of injectable formulations for Type 2 Diabetes management.
- Obesity Treatment: Development of weight-loss therapies targeting appetite suppression.
- Research & Development: Supply for clinical trials investigating metabolic syndrome mechanisms.
Precautions
Contraindicated in patients with personal or family history of medullary thyroid carcinoma. Must be stored at 2°C to 8°C in original packaging. Strict adherence to sterile handling protocols is required during industrial processing.